SINOPSE
This session contrasts the potential for favorable clinical and patient outcomes when incorporating emicizumab into patient management with the
potential consequences focusing on specific hemophilia A subgroups. Speakers will highlight current data, considerations for clinical decision-making,
and gaps in available information in a number of clinical situations including: previously untreated patients (PUPs), managing new FVIII inhibitors
patients and immune tolerance induction, peri-surgical management, non-severe hemophilia, and the aging hemophilia population.
